NASDAQ: ACXPAcurx Pharmaceuticals Inc Stock
$4.11-0.18 (-4.2%)
Updated Dec 11, 2025
ACXP Price
$4.11
Fair Value Price
$4.35
Market Cap
$8.57M
52 Week Low
$3.17
52 Week High
$25.00
P/E
-0.48x
P/B
2.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.68
Operating Cash Flow
-$8M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACXP Overview
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing antibiotics to treat bacterial infections. Its lead candidate is ibezapolstat to treat patients with clostridium difficile infections. Acurx is also developing ACX-375C, a treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals was incorporated in 2017 and is headquartered in Staten Island, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACXP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACXP
Ranked#237 of 489
Ranked#237 of 489
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $320.84 | A | |
| $20.62 | A | |
| $7.16 | A |
Be the first to know about important ACXP news, forecast changes, insider trades & much more!
ACXP News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACXP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACXP ($4.11) is undervalued by 5.58% relative to our estimate of its Fair Value price of $4.35 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACXP ($4.11) is not significantly undervalued (5.58%) relative to our estimate of its Fair Value price of $4.35 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACXP due diligence checks available for Premium users.
Valuation
ACXP fair value
Fair Value of ACXP stock based on Discounted Cash Flow (DCF)
Price
$4.11
Fair Value
$4.35
Undervalued by
5.58%
ACXP ($4.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACXP ($4.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACXP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.48x
Industry
159.38x
Market
45.84x
ACXP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.36x
Industry
5.34x
ACXP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACXP's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
ACXP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.1M
Liabilities
$2.5M
Debt to equity
0.68
ACXP's short-term assets ($6.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACXP's short-term assets ($6.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACXP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$1.7M
ACXP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACXP vs Biotech Stocks
Acurx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.